The mechanism of toxicity for cytolytic lymphocytes of Leu-Leu-OMe and related dipeptide derivatives was examined . Selective inhibition of dipeptidyl peptidase I (DPPI), a lysosomal thiol protease highly enriched in cytotoxic lymphocytes, prevented all natural killer (NK) toxic effects of such agents . However, many DPPI substrates were found to possess no NK toxic properties. For some such agents, this lack of NK toxicity appeared to be related to the lack of uptake by lymphocytes . In this regard, Leu-Leu-OMe was found to be incorporated by lymphocytes and monocytes via a saturable facilitated transport mechanism with characteristics distinct from previously characterized mammalian dipeptide transport processes . This novel transport process was found to be specific for dipeptides composed of selective L-stereoisomer amino acids and enhanced by hydrophobic ester or amide additions to the COOH terminus of dipeptides. Maximal rates of Leu-Lcu-OMe uptake by T8 and NK cell-enriched peripheral blood lymphocytes (PBL) were four-to sixfold higher than for T4-enriched PBL or PBL depleted of Leu-Leu-OMe-sensitive cytotoxic lymphocytes. All dipeptide amides or esters with NK toxic properties were found to act as competitive inhibitors of [3H]Leu-Leu-OMe uptake by PBL . However, some NK nontoxic DPPI substrates were found to be comparable with Leu-Leu-OMe in avidity for this transport process. Such agents were noted to possess one or more hydrophilic amino acid side chains and were found not to mediate red blood cell lysis when subjected to the aryl transferase activity of DPPI. Thus, uptake by a dipeptide-specific facilitated transport mechanism and conversion by DPPI to hydrophobic polymerization products with membranolytic properties were found to be common features ofNK toxic dipeptide derivatives . The presence of a previously unreported dipeptide transport mechanism within blood leukocytes and the selective enrichment of the granule enzyme, DPPI, within cytotoxic effector cells of lymphoid or myeloid lineage appear to afford a unique mechanism for the targeting ofimmunotherapeutic reagents composed ofsimple dipeptide esters or amides.
The mechanism of toxicity for cytolytic lymphocytes of Leu-Leu-OMe and related dipeptide derivatives was examined . Selective inhibition of dipeptidyl peptidase I (DPPI), a lysosomal thiol protease highly enriched in cytotoxic lymphocytes, prevented all natural killer (NK) toxic effects of such agents . However, many DPPI substrates were found to possess no NK toxic properties. For some such agents, this lack of NK toxicity appeared to be related to the lack of uptake by lymphocytes . In this regard, Leu-Leu-OMe was found to be incorporated by lymphocytes and monocytes via a saturable facilitated transport mechanism with characteristics distinct from previously characterized mammalian dipeptide transport processes . This novel transport process was found to be specific for dipeptides composed of selective L-stereoisomer amino acids and enhanced by hydrophobic ester or amide additions to the COOH terminus of dipeptides. Maximal rates of Leu-Lcu-OMe uptake by T8 and NK cell-enriched peripheral blood lymphocytes (PBL) were four-to sixfold higher than for T4-enriched PBL or PBL depleted of Leu-Leu-OMe-sensitive cytotoxic lymphocytes. All dipeptide amides or esters with NK toxic properties were found to act as competitive inhibitors of [3H]Leu-Leu-OMe uptake by PBL . However, some NK nontoxic DPPI substrates were found to be comparable with Leu-Leu-OMe in avidity for this transport process. Such agents were noted to possess one or more hydrophilic amino acid side chains and were found not to mediate red blood cell lysis when subjected to the aryl transferase activity of DPPI. Thus, uptake by a dipeptide-specific facilitated transport mechanism and conversion by DPPI to hydrophobic polymerization products with membranolytic properties were found to be common features ofNK toxic dipeptide derivatives . The presence of a previously unreported dipeptide transport mechanism within blood leukocytes and the selective enrichment of the granule enzyme, DPPI, within cytotoxic effector cells of lymphoid or myeloid lineage appear to afford a unique mechanism for the targeting ofimmunotherapeutic reagents composed ofsimple dipeptide esters or amides. C ells with cytotoxic potential contain a unique array of granule-associated proteins. Thus, specialized cytoplasmic granules containing pore-forming molecules and other toxins, have been noted to be common features of cytotoxic effector cells oflymphoid or myeloid lineage (1-5). A number ofserine esterases also appear to be selectively expressed within the lysosome-like granules of cytotoxic lymphocytes (6-10). In addition, we have recently found that the lysosomal thiol protease, dipeptidyl peptidase I (DPPI)t is present at far higher ' Abbreviations used in this paper: DPPI, dipeptidyl peptidase 1 ; M0, monocytes. 183 levels in cytotoxic lymphocytes than in cells without rytolytic potential or not of bone marrow origin (11) .
The presence of high concentrations ofDPPI within cytotoxic effector cells was noted in the course of studies designed to delineate the mechanisms of the toxic effects of L-leucyl-Lleucine methyl ester (Leu-Leu-OMe) on these cells . The selective toxic effects of Leu-Leu-OMe on human or murine lymphoid or myeloid cells with rytolytic potential had previously been defined (12) (13) (14) (15) , and were found to relate to their unique capacity to metabolize this immunosuppressive agent. After exposure to Leu-Leu-OMe, cytotoxic lymphocytes generated membranolytic products of the structure (Leu-Leu) n OMe, where n >,3 (11) by the aryl transferase activity of the lyso-(T4 cell)-enriched lymphocytes were prepared by incubation of PBL with OKT8 and L243, followed by panning on goat anti-mouse Ig-coated petri dishes and treatment with OKT8, Leu-lib, and C', as previously described (13, 14) .
Cytotoxicity Assays. NK activity against K562 target cells was assessed in 4-h "Cr release assays, and percent specific cytotoxicity was calculated as previously described (16) . In other experiments, human RBC were "Cr labeled and added to microtiter wells (106 RBC/well) in HBSS (200,ul/well) containing 25 mM Hepes and 2 mM DTT and the indicated concentrations of purified bovine DPPI and dipeptide esters or amides. After incubation for 4 h at 37°C, plates were centrifuged at 50 g for 5 min, 100 141 of culture supernatant were harvested from each well, and "Cr release and percent specific lysis calculated as previously detailed (16) .
Assessment of Cell-associated PHILu-Leu-OMe. Cell populations (2 .5 x 106/ml) were incubated at the indicated temperature with 0.2-1 ACi/ml [3H]-labeled Leu-Leu-OMe and the indicated concentrations of unlabeled dipeptide esters for fixed time intervals. The cells were then centrifuged through silicone oil (SF1250; General Electric Co., Waterford, NY) to separate them from external unbound Leu-Leu-OMe. Aliquots of the PBS supernatant and the cell pellet were then assessed for [3H]Leu-Leu-OMe content by liquid scintillation spectroscopy. Control tubes to which no cells had been added were analyzed to quantify the amount of unbound [3H]Leu-Leu-OMe that passed through the silicone oil. All assessments were performed in triplicate, and cell-associated [3H]LeuLeu-OMe was expressed as mean specific cell-associated [3H]LeuLeu-OMe (mean cpm below silicone in tubes with cells added -cpm below silicone oil in tubes without silicone oil), or as an absolute quantity of Leu-Leu-OMe incorporated as calculated from the formula: Leu-Leu-OMe incorporated -[(concentration of Leu-LeuOMe) (Volume of total incubation mixture)] [cpm (cell pellet) -cpm (background)/cpm (cell pellet) + cpm (supernatant)] . In some experiments, Leu-Leu-OMe incorporation was assessed over a broad concentration range, and kinetic constants (Km and Vmax) were calculated from Lineweaver-Buck plots.
Enzyme and Protein Assays . DPPI activity was assayed fluorometrically at pH 5.0 in 0.05 M sodium acetate buffer, 10 mM cysteine, 30 mM NaCl, and 1 mM EDTA with Gly-Phe-o-naphthylamide as substrate, as previously described (17) . In selected experiments, the acyl transferase activity of DPPI was measured by incubation of purified DPPI or cell sonicates with 50 mM dipeptide ester, 25 mM DTT, 0.4 M hydroxylamine.HCI at pH 6.8 for 20 min at 37°C, as previously detailed (18) . The reaction was stopped by addition of equal volumes of 20% trichloroacetic acid. The supernatant was then mixed with 1/2-vol 5% FeC13.6HZ0 in 0.1 M HCl and 1 vol H20, and the absorbance at 510 nM was measured. Cathepsin B was assayed at pH 6.3 in 0.1 M sodium phosphate buffer, 1 mM EDTA, 10 mM cysteine with Z-Arg-Arg-0-naphthylamide as substrate, as previously described (19) . Protein content was assessed by reaction with bicinchoninic acid, as previously described (20) .
Results
DPPI has been shown previously to possess acyl transferase activity that converts dipeptide amide or dipeptide ester substrates to polymerization products of the general structure (Rl -R2)n -NH2 or (Rt -R2) -OR3 when RI is not arginine, lysine, or proline, and RZ is not proline (21) (22) (23) (24) . The acyl transferase activity of DPPI has been demonstrated to play an essential role in Leu-Leu-014e-mediated toxicity for human cytolytic cells (11) , but its potential role in mediating toxicity of other related compounds has not been determined. The experiments detailed in Table 1 were therefore carried out to examine the role of DPPI in the sensitivity of cytolytic cells to other dipeptide esters or amides. Since the sensitivity of NK cells to these compounds parallels that of CTL, for convenience, NK cells were used in these experiments (11, 13) .
As demonstrated in experiment 1 (Table 1) , incubation of (23) . Consistent with this, we have found that both Gly-Phe-/3-naphthylamide and Gly-Arg-a-naphthylamide are efficiently degraded by PBL lysates or purified bovine DPPI, with the latter a better substrate than the former (data not shown) . Despite this, as demonstrated in experiment 2 (Table 1) , NK function was ablated by exposure to modest concentrations of Gly-Phe-(3-naphthylamide, whereas Gly-Arg-a-naphthylamide was not NK toxic, even at a 100-fold higher concentration. In addition, Leu-Leu-NH2, another substrate of DPPI, was not NK toxic at 1 mM, as demonstrated in experiment 4 (Table 1) . These results indicate that substrates of DPPI differ in their capacity to cause NK cell toxicity. Additional complexity in this system was indicated by the finding that Ser-Leu-OMe was able to inhibit the toxic effects of Leu-Leu-OMe on NK cells, even though it was not directly toxic for NK cells. Thus, as shown in experiment 3 (Table 1) , PBL were completely protected from the NK toxic effects of 25-50 AM Leu-Leu-OMe by 250 AM Ser-Leu-OMe, and partially protected from the effects of 100 AM Leu-Leu-OMe. By contrast, the presence of a 10-fold excess of Leu-Leu-NH2 (experiment 4, Table 1 ) afforded no protection from the NK toxic effects of Leu-Leu-OMe. The inability of either Ser-Leu-OMe or Leu-Leu-NH2 to exert toxic effects on NK cells, and the differences in their capacities to inhibit Leu-Leu-OMe-mediated NK toxicity, suggested that being a substrate for DPPI was not sufficient for a dipeptide methyl ester or amide to be toxic for NK cells.
Other features of the molecule appeared to be necessary for this action .
Other possible steps involved in the toxicity of a dipeptide methyl ester for NK cells could be the uptake of the compound by the cell and/or the generation of a membranolytic molecule by the action of DPPI. The next experiments, therefore, examined the mechanism ofthe uptake of Leu-Leu-OMe by human PBL to determine whether a specific transport mechanism was involved . As detailed in Fig. 1 , the quantity of cell-associated [3H]Leu-Leu-OMe increased in a linear, timedependent fashion over the first 30 min of incubation ofhuman PBL with 250 AM Leu-Leu-OMe at room temperature . As demonstrated in Table 2 , when incubations were carriedout at temperatures <4°C, no accumulation of [3H]Leu-LeuOMe by PBL was detected . After incubation at 37°C, levels of cell-associated Leu-Leu-OMe were increased above those seen at 22°C (experiment 2, Table 2 ). These findings suggested that Leu-Leu-OMe was not simply binding to PBL by an energy-or temperature-independent process. Rather, 18 6 Cytotoxic Cell Toxicity of Leucyl-Leucine Methyl Ester the time-and temperature-dependent increases in cell-associated Leu-Leu-OMe suggested that this compound was being internalized and retained by PBL . When the concentration dependence of Leu-Leu-OMe uptake by various subpopulations ofhuman PBMC was assessed (see Fig. 2 ), the quantity of Leu-Leu-OMe incorporated during a 15-min incubation at 22°C was noted to increase in direct proportion to the external concentrations until 100 AM was exceeded, at which point the saturable characteristics of this uptake process became apparent. Differences in the uptake ofLeu-Leu-OMe by different subpopulations of PBMC were noted . Thus, T8 and NK cells incorporated three-to fourfold greater quantities of Leu-Leu-OMe than did T4 cells (see Fig. 2 Lou-Leu-OMe Concentration (uM) Figure 2 . Concentration-dependent uptake of Leu-Leu-OMe by human M0 and lymphocytes . The indicated cell populations were incubated for 15 min at 22°C with varying concentrations of Leu-LeuOMe and the quantity of Leu-Leu-OMe incorporated, as detailed in Fig. 1 and Table 2 . Values are given for mean ± SE of triplicate determinations.
Despite the variability in maximal uptake of Leu-Leu-OMe by the various populations of PBMC, Leu-Leu-OMe incorporation in all cases was mediated by a saturable process with a Km of 100-200 P.M (Table 3 ; additional experiments not shown) .
To determine whether cells with a greater capacity to take up Leu-Leu-OMe were the cells selectively killed by exposure to this agent, PBL were incubated in the presence or absence of 250 fiM Leu-Leu-OMe for 15 min at 22°C and then washed Table 3 . Rates of Leu-Leu-OMe Uptake and DPPI Content of Monocytes and Lymphocyte Subpopulations " Data are provided for the cell populations isolated from a single peripheral blood sample. t Kinetic constants calculated by least squares fit in Lineweaver Burk plots of Leu-Leu-OMe uptake assessed at concentrations of 4, 16, 64, 256 and 1,024 AM . All coefficients of correlation were >0 .95.
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Thiele and Lipsky and cultured for 18 h at 37°C before assessment of Leu-LeuOMe uptake. These treatment conditions have been previously shown to result in the death of 20-50% of PBL (13) . The majority of PBL, however, remain viable and functionally intact (13) . As illustrated in Table 3 , Leu-Leu-OMe-resistant PBL depleted of NK and CTL by Leu-Leu-OMe treatment (12, 13) were noted to incorporate Leu-Leu-OMe at approximately half the rate of untreated control PBL. As demonstrated by the data detailed in Table 3 , cell populations with higher DPPI concentrations (T8, NK cells, or MO) generally were found to incorporate [3H]Leu-Leu-OMe at greater rates than was observed for relatively DPPI-deficient T4 cells or Leu-Leu-OMe-treated PBL. Thus, T8-and NKenriched PBL were found to contain approximately eightfold more DPPI activity and to incorporate Leu-Leu-OMe at a fourfold greater rate than did T4-enriched PBL. In addition, Leu-Leu-OMe-resistant PBL had a four-to fivefold lower DPPI content and incorporated Leu-Leu-OMe at approximately half the rate of control PBL. Despite the apparent correlation between DPPI content and Leu-Leu-OMc incorporation, the Leu-Leu-OMe uptake measured in these studies was not simply a reflection of retention of Leu-Leu-OMe products of DPPI metabolism . Thus, in the experiment detailed in Fig. 3 , unseparated PBL or T8-and NK-enriched populations were preincubated with 10 -5 M Gly-Phe-CHN2 . Although incubation with Gly-Phe-CHN2 routinely leads to >95% inhibition of intracellular DPPI activity (Table 1) , LeuLeu-OMe uptake by cells treated with this specific DPPI inhibitor was not significantly altered. Thus, Leu-Leu-OMe uptake appears to involve mechanisms distinct from the enzymatic activity of DPPI .
Peptide transport processes have been described in a variety of mammalian tissues (26) . The experiments detailed in Table 4 were carried out to determine whether the uptake 500 1000 1500
Leu-Leu-OMe Concentration CUM) Figure 3 . Concentration-dependent uptake of Leu-Leu-OMe is not affected by pretreatment with the DPPI inhibitor Gly-Phe-CHN2 . The indicated cell populations were incubated for 1 h in the presence or absence of 10 -5 M Gly-Phe-CHN2 The cells were then washed and assessed for concentration-dependent Leu-Leu-OMe uptake, as detailed in Fig. 2 . `Leu-Leu-OMe uptake was assessed after incubation of PBL for 15 min at 22°C in the presence of 100 #M Leu-Leu-OMe. Values are given for mean ± SE of triplicate determinations . 1 PB, phosphate buffer composed of Na2P04 and NaHP04.
of Leu-Leu-OMe by human PBL is mechanistically similar to dipeptide transport processes previously characterized in the intestinal tract, renal tubule, or the brain (26) (27) (28) (29) (30) (31) . Intestinal and renal tubular dipeptide transport has been shown to be an active proton-coupled process that proceeds optimally at extracellular pH of 5.5-6 .0 (27, 28, 31) . However, as indicatedby the results detailed in Table 4 , Leu-Leu-OMe uptake by human PBL is decreased rather than increased when extracellular pH is decreased from 7.4 to 6.0. Furthermore, rates of Leu-Leu-OMe uptake were unaffected by addition of the metabolic inhibitor, sodium azide, or by the presence or absence ofextracellular glucose or sodium, additionally demonstrating that its uptake by PBL proceeds by a mechanism that is different than the aforementioned dipeptide transporters (26) (27) (28) (29) (30) (31) . Additional experiments were carried out to assess the specificity of this transport process. Various structural analogues of Leu-Leu-OMe were examined for the capacity to inhibit the uptake of [3H]Leu-Leu-OMe . The results of experiments depicted in Fig. 4 demonstrate that uptake of [3H]Leu-Leu-OMe is competitively inhibited not only by addition o£ excess unlabeled Leu-Leu-OMe, but also by excess unlabeled Val-Phe-OMe or Ser-Leu-OMe . The virtually identical concentration-dependent patterns of inhibition of [3H]Leu-Leu-OMe uptake by these three unlabeled dipeptide methyl esters suggested that these compounds were competing for a common facilitated transport mechanism. Additional experiments were carried out to explore the structural characteristics of compounds that competitively inhibit [3H]LeuLeu-OMe uptake in greater detail . As demonstrated by the results in Table 5 , [3H]Leu-Leu-OMe uptake is competitively inhibited not only by excess quantities of unlabeled Leu-Leu-OMe, but also by high concentrations of the dipeptide Leu-Leu and by other esters of Leu-Leu such as Leu-LeuOBenzyl . However, neither Leu-OMe nor Leu-Leu-Leu-OMe were observed to compete with lymphocyte incorporation of Leu-Leu-OMe . Furthermore, neither the D-stereoisomer of Leu-Leu-OMe nor the amide analogue Leu-Leu-NH2 inhibited uptake ofthe dipeptide methyl ester. Thus, the saturable process whereby Leu-Leu-OMe is incorporated into PBL is restricted to dipeptides or dipeptide derivatives . In addition, as demonstrated by the experiments in Table  6 , not all dipeptide methyl esters composed ofL-stereoisomers of naturally occurring amino acids can effectively compete with [3H]Leu-Leu-OMe uptake. Thus, excess concentrations of unlabeled Pro-Leu-OMe or Asp-Leu-OMe had no discernible effect on the uptake of [3H]Leu-Leu-OMe. Of note, nei- " Assessed as detailed in Table 3 . In all cases, SEM was 510% . t Calculated from previously published data (12) LD50 determined from the concentration required to ablate 50% of cytotoxicity/activity of NAC assayed against K562 targets at a 20:1 E/T ratio.
ther Pro-Leu-OMe nor Asp-Phe-OMe caused significant NK toxicity, whereas compounds such as Val-Phe-OMe and LeuPhe-OMe not only shared the NK toxicity ofLeu-Leu-OMe, but also appear to share the same lymphocyte uptake pathway, as they are virtually identical to unlabeled Leu-Leu-OMe in the capacity to inhibit the uptake of [3H]Leu-Leu-OMe . Lack of affinity for this facilitated transport pathway, however, could not explain the lack of NK toxicity of LeuTyrOMe or Ser-Leu-OMe, as these compounds were noted to inhibit [3H]Leu-Leu-OMe incorporation very effectively. The results suggested that for some dipeptide esters such as Ser-Leu-OMe or LeuTyr-OMe, lack of toxicity for DPPIrich cytolytic lymphocytes could not be explained by the inability to be taken up by lymphocytes or by the lack of known substrate affinity for DPPI. Experiments were therefore carried out to determine whether DPPI-generated metabolites of such dipeptide esters exhibited membranolytic potential . As previously reported and as detailed in Fig. 5 (upper left) , when 5'Cr-labeled human RBC were incubated with varying concentrations ofLeu-Leu-OMe alone or with DPPI alone, no damage to cell membranes was apparent. However, in the presence of 250 /AM or more Leu-Leu-OMe and DPPI, lysis ofRBC was noted. This membranolytic effect has been demonstrated previously (11) to be mediated by Leu-Leu-OMe polymerization products of the general structure (Leu-Leu)-OMe, when n >3.
Leu-Leu-NH2 proved to be an equally good substitute for production ofmembranolytic DPPI metabolites, whereas the benzyl ester derivative of Leu-Leu was found to be an even more effective substrate for this process. Substitution of Dstereoisomers of Leu into both positions of Leu-Leu-OMe or either the NH2-terminal or penultimate position of this substrate (data not shown) led to no DPPI-catalyzed membranolytic effects. The lack of RBC lysis in the presence of 189 Thiele and Lipsky DPPI and D-stereoisomers of Leu-Leu-OMe likely is related to the fact that the aryl transferase activity of this enzyme is seen only with dipeptide substrates composed entirely of L-stereoisomer-containing amino acids (22, 24) . However, use of this assay system in additional experiments revealed that DPPI-catalyzed RBC lysis was observed when NK-toxic dipeptide esters such as Leu-Phe-OMe or Val-Phe-OMe were used, but not when the putative DPPI substrates Ser-Leu-OMe or Leu Tyr-OMe were used. That compounds such as Ser-LeuOMe indeed bind to the active site of DPPI is shown by the results of the experiment detailed in Fig. 6 . In this experiment, excess quantities of Ser-Leu-OMe were noted to inhibit RBC lysis mediated by the combination of DPPI and 250-1000 p,M Leu-Leu-OMe. In additional experiments, LeuTyr-OMe also was observed to inhibit RBC lysis mediated by DPPI + Leu-Leu-OMe (data not shown) .
A number of additional dipeptide esters and amides were also screened in each of these assays to determine the nature of active compounds in greater detail. As summarized for representative compounds in Table 7 , competitive inhibition of [3H]Leu-Leu-OMe uptake was seen with dipeptides or dipeptide methyl esters composed ofuncharged L-stereoisomer amino acids. Addition of somewhat more hydrophobic benzyl ester or R-naphthylamide derivatives favored competition with the transporter responsible for Leu-Leu-OMe incorporation by PBL, whereas simple amide or methyl amide derivatives demonstrated no avidity for this transport system . Only dipeptide esters or amides composed entirely of nonpolar R group L-stereoisomer amino acids were converted to RBC lytic products by DPPI. Thus, all NK toxic dipeptide derivatives have been noted to act both as competitive inhibitors of [3H]]LeuLeu-OMe uptake by human PBL and to serve as substrates for DPPI-catalyzed lysis ofhuman RBC. In contrast, all dipeptide ester or amides that at a concentration of 250 p,M exert no effect on NK cell function have proven to be inactive in one or both of these assays . Finally, NK cells pretreated with the specific DPPI inhibitor Gly-Phe-CHN2 are resistant to any discernible toxic effects of any of the dipeptide esters or amides screened in these studies .
The results summarized in Table 7 imply that Ser-Leu-OMe and LeuTyr-OMe lack NK toxic effects because DPPI polymerization products of these compounds lack membranolytic effects . To verify that this was the basis for the lack of NK toxicity of these compounds, the experiments detailed in Table  8 were performed . Uptake of these compounds by cytolytic cells was directly measured, as was their capacity to serve as substrates for DPPI-mediated transamidation enriched PBL and are suitable substrates for transpeptidation by the DPPI activity present within cytotoxic lymphocytes. The inability of the compounds to exert toxicity for cytolytic cells, therefore, appears to result from the lack of membranolytic properties of the transpeptidation products.
Discussion
The present studies elucidate several common characteristics of NK toxic dipeptide esters and amides . The results not 190 Cytotoxic Cell Toxicity of Leucyl-Leucine Methyl Ester Figure 5 . RBC lysis is mediated by DPPI metabolites of some but not all ester or amide derivatives of Leu-Leu . s'Cr-labeled human RBC were incubated in the presence (O) or absence (') of 8 x 10 -4 U/ml of DPPI, and the indicated concentrations of dipeptide esters or amides for 4 h at 37°C and were then assessed for percent specific lysis .
only document the metabolic steps involved in the toxicity to cytotoxic cells, but have also delineated a new transport system for dipeptides . The observations indicate that uptake via a facilitated transport mechanism and conversion to hydrophobic polymerization products by the granule protease, DPPI, are essential steps in the mechanism, whereby dipeptide esters mediate toxic effects toward cytolytic lymphocytes . These findings not only provide a basis for design and synthesis of dipeptide analogues that may mimic the unique immunosuppressive effects of Leu-Leu-OMe, but also provide new insights into the manner in which lymphocytes process these small peptide derivatives . It has been demonstrated previously that active transport of di-and tripeptides occurs in mammalian small intestine, as well as in tissues or cells isolated from a variety of other organs (26) . A number of pharmaceutical agents of analogous structure, including O-lactam antibiotics and the angiotensin-converting enzyme inhibitor captopril, are also transported through these peptide carrier systems (32) . Peptide transport in intact small intestine or renal tubules is mediated by an active, low affinity process with a Km in the 5-10 mM range (32) (33) (34) . When dipeptide transport has been assessed in intestinal or renal brush border vesicles, the Km of this process has been found to be N1 mM (35) . In contrast, the present studies indicate that human PBL incorporate Leu-Leu-OMe via a relatively high affinity transport mechanism with a Km of 100-200 /AM. Furthermore, no change in the rate of Leu-Leu-OMe uptake by PBL was noted in the presence of azide and/or in the absence of extracellular glucose or Na' . Thus, we have found no evidence to suggest that dipeptide or dipeptide ester uptake by human PBL is an energy-requiring process . Rather, the transport process appears to facilitate movement ofmolecules down a concentration gradient . Thus, when lymphocyte volume estimated by light scatter was used to determine the overall intracellular concentration of Leu-Leu-OMe achieved after a 15-min incubation, it was found to approximate no more than 5% of the extracellular concentration . Therefore, the present data regarding lymphocyte uptake of Leu-Leu-OMe are most consistent with a facilitated diffusion process mediated by a high affinity carrier. Furthermore, the absence of a requirement for extracellular Na+ and the lack of enhancement of PBL dipeptide transport in the presence of decreased extracellular pH suggests that unlike amino acid or dipeptide transport 191 Thiele and Lipsky in other cell types, Leu-Leu-OMe uptake by PBL was not coupled to Na+ or H+ gradients (27) (28) (29) (30) (31) . A high affinity peptide transport process with Km and Vmax values similar to those detected in the present studies has been observed in astroglial-rich brain cell cultures (29) . However, dipeptide uptake by astroglial cells has been demonstrated to be an energy-dependent process that is inhibited by extracellular Na' depletion, by inhibition of ATP production, or by the addition ofa variety of tri-or oligo-peptides (29) . Therefore, this astroglial cell peptide transport system, as well as dipeptide transport mechanisms previously characterized in the intestine or renal tubule, appear to be distinct from the dipeptidespecific facilitated transport process elucidated in the present studies.
Wheras simple dipeptides such as Leu-Leu appear to utilize the same PBL transport process as Leu-Leu-OMe, the present studies indicate that binding to this transporter is facilitated by nonpolar ester or amide additions to the COOH terminus of dipeptides. The lack of competitive inhibition of Leu-Leu-OMe uptake by excess concentrations of Leu-OMe or Leu-Leu-OMe suggests that this transport process is strictly specific for dipeptide derivatives. As not all dipeptide esters competitively inhibit Leu-Leu-OMe uptake, the membrane carrier responsible for this process appears to be selective with regard to dipeptides that can be transported . In the current studies, this transport system was assessed for the capacity to internalize Leu-Leu-OMe and other dipeptide ester or amide substrates of DPPI. It is also possible, however, that under physiologic conditions, the same peptide carrier may be responsible for facilitating egress of dipeptide products of proteasemediated degradation of oligopeptides or proteins.
In addition to characterizing the mechanism for internalization of NK toxic dipeptide derivatives, the present studies also demonstrate that NK toxicity mediated not only by LeuLeu-OMe, but also by a variety of other dipeptide esters or amides, is prevented by preincubation of these cells with a specific inhibitor of the lysosomal thiol protease, DPPI. In previous studies, it has been demonstrated that this enzyme is responsible for conversion of Leu-Leu-OMe to oligomers of the general structure (Leu-Leu) -OMe (11) . The present studies confirm that serving as a substrate for the transpeptidase activity of DPPI is an essential characteristic ofNK toxic dipeptide esters or amides. However, this attribute is not sufficient to induce NK toxic effects . Thus, DPPI substrates such as Ser-Leu-OMe and Leu Tyr-OMe mediated no NK toxic effects when present at concentrations well in excess of concentrations of Leu-Leu-OMe that cause ablation of all NK activity. These agents are equal to Leu-Leu-OMe in the capacity to inhibit [3H]Leu-Leu-OMe uptake by PBL, and therefore appear to utilize the same transport mechanism . Furthermore, direct measurements ofSer-Leu-OMe and LeuTyr-OMe uptake by PBL reveal that lymphocyte incorporation rates of these dipeptide esters are equal to or superior to that of Leu-Leu-OMe . Thus, the lack of NK toxicity is not related to any inability of NK cells to internalize these agents. However, unlike Leu-Leu-OMe and other dipeptide esters or amides composed of amino acids with relatively hy- Tables 5 and 6 ; >66% inhibition, + + ; >33% inhibition, + ; <33% inhibition, -. t Assayed as detailed in Fig. 6 ; >33% RBC lysis at 250 AM, + + ; <33% RBC lysis at 250, >33% lysis at 1 mM, + ; <33% lysis at 1 mm, -. 5 NK toxicity assessed as detailed in Table 1 . >50% loss of NK function, E/T 10 :1 ; dipeptide concentration 50 AM, + + ; <50% loss of NK function at 50 AM but >50% at 250 AM, + ; <50% loss NK function at 500 AM, -.
II Toxicity assessed as above for cells preincubated for 30 min at 37°C with 10-5 M Gly-Phe-CHNz before exposure to 50-500-pM concentrations of the indicated compound .
drophobic R groups, DPPI substrates with polar R group amino acids in either position do not serve as adequate substrates for DPPI-catalyzed lysis of RBC . These polar R groupcontaining dipeptide esters, however, are capable of competitively inhibiting RBC lysis mediated by the combination of DPPI and Leu-Leu-OMe, and can serve as substrates for the acyl transferase activity ofDPPI, as has been previously indicated (22, 24) . These results, therefore, suggest that (SerLeU)n-OMe or similar polymers form within the granule compartment of cytotoxic lymphocytes but have no mem- ]Me (sp act 1 .34 mCi/mM) by T8-and NK-enriched PBL was assessed during a 5-min incubation at 22°C. i Purified bovine DPPI was present at a concentration of 10-2 U/ml . 5 T8-and NK-enriched cells (107/ml in saline) were sonicated and mixed with equal volumes of substrate buffer solutions containing 100 mM dipeptide ester, 50 mM DTT, and 0.8 mM hydroxylamine.HCI . Reactions mixtures containing equal concentrations of TS and NK cell sonicates treated with 10-4 M Gly-Phe-CHN2 were used as blanks so that only DPPI-mediated transmidation could be assessed . branolytic properties, and hence, no toxic effects . Thus, the generation of membranolytic products from dipeptide esters or amides only occurs with DPPI substrates uniformly composed of hydrophobic amino acids. Of note, in the 5'Cr-labeled RBC assay in which this membranolytic effect has been directly observed, DPPIcatalyzed RBC lysis is only observed in the presence of >250 FAM concentrations ofdipeptide ester or amide substrates . Despite this, the calculated intracellular concentration of LeuLeu-OMe achieved after exposure to NK toxic concentrations of Leu-Leu-OMe may be as low as 1-5 /AM. Several factors may account for this apparent discrepancy. The lysosomotropic characteristics ofamino acid and peptide esters have been previously well characterized (36, 37) . Therefore, although average intracellular concentrations of Leu-Leu-OMe achieved after exposure of T8-and NK-enriched PBL to 50-100 AM Leu-Leu-OMe may be only 1-5 IAM, the concentration of this agent within the DPPI-containing granule compartment of these cells may be much higher. In addition, introduction of membranolytic extensively hydrophobic (Leu-Leu)n OMe metabolites into appropriate cell membranes may be far more efficient when these DPPI products are produced within a cell rather than in the external aqueous medium used in the 5'Cr-labeled RBC lysis assays. These results, therefore, are still consistent with a primary role for the membranolytic effects of (Leu-Leu)oOMe products in the generation of Leu-Leu-OMe-mediated killing of cytolytic lymphocytes. It remains to be determined whether the membranolytic (LeuLeu),;OMe, n >3 products of this enzyme trigger other unique enzymatic events in cells with endogenous cytolytic capacity that also contribute to the restricted spectrum of toxicity of Leu-Leu-OMe and related compounds.
The toxic effects of Leu-Leu-OMe on human and murine cells have been noted to be highly selective with only rytotoxic lymphocytes and cells of myeloid origin killed after brief exposures to 50-500 P,M Leu-Leu-OMe (13, 15) . In contrast, Th cells, B cells, and a variety of cells of non-bone marrow origin remain functionally intact after such exposures (13, 15) . The present studies demonstrate that facilitated transport of the dipeptide ester is an essential step in the toxicity caused by these agents. Both Leu-Leu-OMe-sensitive and LeuLeu-OMe-resistant cell types transport dipeptides with a similar avidity (Km) but with two-to sixfold disparate capacity (Vmax). Thus, differential rates ofLeu-Leu-OMe uptake are likely to contribute to the selective nature of this toxicity. 8-10-fold differences in DPPI content of Leu-LeuOMe-sensitive and Leu-Leu-OMe-resistant cells have also been noted (11) . Therefore, it is likely that the relative enrichment of this granule enzyme within rytotoxic lymphocytes and myeloid cells also plays a significant role in determining susceptibility to Leu-Leu-OMe and related compounds. Whereas DPPI-like activity has been demonstrated in a host of mammalian organs and cell types, the detection of marked enrichment of this enzyme within rytotoxic lymphocytes and myeloid cells, as well as the existence of a facilitated transport system to deliver substrates of this enzyme, provide a unique means of targeting agents with the capacity to selectively delete rytotoxic cells .
